Gland Pharma Limited — Important, 18-01-2025: Updates

The US FDA has concluded its inspection at Gland Pharma's Pashamylaram Facility in Hyderabad, following its review for Good Manufacturing Practices (GMP) conducted between July 25 and August 2, 2024. The company has received the Establishment Inspection Report (EIR) confirming the closure of this inspection. This positive outcome not only reinforces the facility's compliance with regulatory standards but also enhances Gland Pharma's operational credibility, potentially aiding in smoother market access and future growth opportunities in both domestic and international markets. Investors should view this development favorably as it may influence the company's operational efficiency and overall market standing.